| Summary: | Plk4 is the most divergent member of the family of polo like kinases (Plks). Plk4-/- embryos arrest at approximately day 7.5 p.c. but Plk4+/- mice are viable and fertile. However, 50% of Plk4+/- mice develop spontaneous tumours of the liver, lung and soft tissues by 2 years of age. Here I investigate the mechanisms that underlie Plk4-related tumourigenesis.
Plk4+/- murine embryonic fibroblasts (MEFs) spontaneously become immortal in vitro with increasing passage number and are tumourigenic in vivo when injected into NOD SCID mice. Cytogenetic analysis showed that Plk4 deficient cells are chromosomally unstable with a large number of chromosomal aberrations and increased ploidy. These results demonstrate that early loss of a single Plk4 allele is sufficient to drive cell immortalization, chromosomal instability and tumourigenicity in vivo.
In two independent expression array analyses, gene expression patterns that would decrease cell migration were overrepresented in Plk4+/- MEFs. A series of spreading and migration assays functionally validated these results, supporting the hypothesis that Plk4 regulates cell motility. Endogenous Plk4 localized to filopodia and lamellipodia in motile cells and to protrusions of spreading cells; the latter localization was transient and it disappeared by 4h after cell seeding, at which point Plk4 was located in the centrosomes, as typically observed in interphase cells. Transient transfection with Flag-Plk4 enhanced spreading and migration, as well as actin remodeling. Taken together, these data demonstrate temporal regulation of Plk4 in relation to the process of membrane remodeling, and a functional role for Plk4 in cell motility.
Plk4 is haploinsufficient for tumour suppression in mice. Plk4 is located at human chromosome 4q28, a region often deleted in primary liver cancer specimens. Here I show that loss-of-heterozygosity (LOH) occurs at the Plk4 locus in ≈50% of human hepatocellular carcinomas (HCC) as well as in preneoplastic cirrhotic liver nodules. LOH at Plk4 is associated with reduced Plk4 expression in HCC tumours, but not with mutations in the remaining allele. These results implicate Plk4 as a potential haploinsufficient tumour suppressor in the genesis of human HCC. With continuing high rates of the predisposing conditions Hepatitis B and non-alcoholic steatohepatitis, and delayed diagnosis, HCC is a global health issue and carries a grave prognosis. A better understanding of genetic predisposition will help guide future screening programs.
|
|---|
